Quantification of desferrioxamine and its iron chelating metabolites by high-performance liquid chromatography and simultaneous ultraviolet-visible/radioactive detection.
An HPLC-based method for quantification of desferrioxamine (DFO) and its iron chelating metabolites in plasma has been developed. This assay overcomes stability problems associated with DFO by the addition of radioactive iron to convert unbound drug and metabolites to radio-iron-bound species. A dual detection system utilizing uv-vis absorption and radioactive (beta-particle) detector was used to quantify total and radio-iron-bound species. The use of octadecyl silanol solid phase extraction cartridges permits concentration of samples and allows accurate quantification of drug and metabolites down to 0.1 nmol/ml.
Singh
S
S
Chelsea Department of Pharmacy, King's College, University of London, United Kingdom.
Mohammed
N
N
Ackerman
R
R
Porter
J B
JB
Hider
R C
RC
D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D003676:Deferoxamine / Q000032:analysis* / Q000097:blood; D006801:Humans; D007501:Iron / Q000097:blood; D007502:Iron Chelating Agents / Q000032:analysis*; D008027:Light; D014466:Ultraviolet Rays
D007502:Iron Chelating Agents; D007501:Iron; D003676:Deferoxamine